Kirsi Ketola

List of Publications by Citations

23 papers	1,076 citations	15 h-index	32 g-index
34 ext. papers	1,289 ext. citations	7.1 avg, IF	3.8 L-index

#	Paper	IF	Citations
23	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. *Cancer Discovery*, **2017**, 7, 54-71	24.4	173
22	High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. *Clinical Cancer Research*, **2009**, 15, 6070-8	12.9	148
21	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. *Oncotarget*, **2013**, 4, 502-30	3.3	131
20	Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. *British Journal of Cancer*, **2012**, 106, 99-106	8.7	114
19	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. *American Journal of Pathology*, **2011**, 178, 525-36	5.8	80
18	High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. *Oncotarget*, **2013**, 4, 48-63	3.3	74
17	Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. *Molecular Cancer Therapeutics*, **2010**, 9, 3175-85	6.1	67
16	PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. *Cancer Research*, **2009**, 69, 2870-7	10.1	65
15	Using online game-based platforms to improve student performance and engagement in histology teaching. *BMC Medical Education*, **2019**, 19, 273	3.3	46
14	Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. *Endocrine-Related Cancer*, **2015**, 22, R165-82	5.7	39
13	Targeting Lyn regulates Snail family shuttling and inhibits metastasis. *Oncogene*, **2017**, 36, 3964-3975	9.2	25
12	Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. *PLoS ONE*, **2012**, 7, e51470	3.7	23
11	Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. *Clinical Cancer Research*, **2017**, 23, 6923-6933	12.9	22
10	CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells. *Cells*, **2019**, 8,	7.9	17
9	The Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. *Molecular Cancer Research*, **2019**, 17, 2154-2168	6.6	16
8	Axon Guidance-Related Factor FLRT3 Regulates VEGF-Signaling and Endothelial Cell Function. *Frontiers in Physiology*, **2019**, 10, 224	4.6	9
7	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. *Journal of Molecular Biochemistry*, **2016**, 5, 12-22	0.2	7

List of Publications

6	BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation. *Oncogene*, **2020**, 39, 2391-2407	9.2	6
5	Thermal dose as a universal tool to evaluate nanoparticle-induced photothermal therapy. *International Journal of Pharmaceutics*, **2020**, 587, 119657	6.5	6
4	Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression. *Cancers*, **2021**, 13,	6.6	6
3	Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population **2012**,		2
2	Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. *Cancer Research*, **2021**, 81, 4901-4909	10.1	0
1	The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts. *Molecular and Translational Medicine*, **2017**, 71-91	0.4	